We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test
News

Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test

Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test
News

Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Omega Diagnostics Group PLC Launches VISITECT® CD4 Point-of-care Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

VISITECT® CD4, developed by the Burnet Institute in Melbourne, Australia, is an affordable POC test that enables CD4 T-cell levels to be determined, quickly and conveniently, even in remote rural areas in resource-poor countries. This easy-to-use, semi-quantitative lateral flow test uses a finger-prick blood sample and produces a straightforward visual result in just 40 minutes, enabling patients to receive life-saving antiretroviral treatment before leaving the clinic. Minimal training is required and no additional instruments are necessary, eliminating the need for sophisticated equipment, expensive reagents and highly trained personnel.

Associate Professor David Anderson, Deputy Director of the Burnet Institute and leader of the team that developed the test, added: “According to UNAIDS, there are 15 million people who should be getting access to antiretroviral therapy but aren’t, just because they can’t get access to an affordable CD4 test in their communities. This test will provide access for even the most remote and disadvantaged patients.”
Andrew Shepherd, Founder and Chief Executive of Omega Diagnostics added: “This test overcomes many of the limitations commonly associated with the traditional technique of flow cytometry, offering a cost-effective means of obtaining immediate CD4 results. Establishing when a patient should commence therapy will improve health and help to reduce transmission of the virus, benefitting the entire population.”

Advertisement